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The significance of macrophage phenotype in
cancer and biomaterials
Hannah C Bygd1, Kiva D Forsmark2 and Kaitlin M Bratlie1,2,3*
Abstract
Macrophages have long been known to exhibit heterogeneous and plastic phenotypes. They show functional diversity
with roles in homeostasis, tissue repair, immunity and disease. There exists a spectrum of macrophage phenotypes with
varied effector functions, molecular determinants, cytokine and chemokine profiles, as well as receptor expression. In
tumor microenvironments, the subset of macrophages known as tumor-associated macrophages generates byproducts
that enhance tumor growth and angiogenesis, making them attractive targets for anti-cancer therapeutics. With respect
to wound healing and the foreign body response, there is a necessity for balance between pro-inflammatory, wound
healing, and regulatory macrophages in order to achieve successful implantation of a scaffold for tissue engineering. In
this review, we discuss the multitude of ways macrophages are known to be important in cancer therapies and
implanted biomaterials.
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Introduction
Heterogeneity of Macrophages
Macrophages are considered to be functionally hetero-
geneous cells with different phenotypes representing
distinct sublineages [1,2]. The heterogeneity of these
cells is attributed to their location in the tissue, due to
microenvironmental signals that control the functional
phenotype [1,3-5]. In the presence of specific microen-
viromental signals, macrophages are able to switch from
one phenotype to another, indicating that these cells have
a degree of plasticity in addition to heterogeneity [3,6]. In
general, heterogeneity of macrophages can be described as
a spectrum of phenotypes [1-3,6-10]. One end represents
classical macrophages activated with interferon (IFN)-γ, M
(IFN-γ), and at the other end alternative macrophages
activated by interleukin (IL)-4, M(IL-4) [7,8,11-15]. This
new nomenclature, recently proposed by Murray et al.,
more accurately reflects the individual phenotypes and po-
larizations of these cells. Other variations of macrophages
that lie along this spectrum include: M(Ic), activated by
immune complexes (Ic); M(IL-10); those stimulated by
glucocorticoids (GC) and transforming growth factor
(TGF)-β, M(GC + TGF-β); M(GC); M(LPS), activated by
lipopolysaccharides; and M(LPS + IFN-γ) [3,6,8-10]. Each
of these phenotypes varies in their effector functions, mo-
lecular determinants, cytokine and chemokine profiles, as
well as receptor expression.
Overall, classically activated, formerly referred to as M1,
macrophages are known to be pro-inflammatory and cyto-
toxic. Macrophages are skewed towards this phenotype
when IFNs and toll-like receptor (TLR) signaling activate
IFN regulatory factor/signal transducers and activators of
transcription (IRF/STAT) signaling pathways via STAT1
[7,10,15-18]. This transcription factor then causes macro-
phages to upregulate IRF5, which is essential for pro-
duction of large amounts of pro-inflammatory cytokines
[16], including tumor necrosis factor (TNF)-α, IL-1β, IL-1,
IL-6, IL-8, IL-12, IL-15, IL-18, and IL-23 that elicit both
T-helper (Th)1 and Th17 responses [9,16,18-20]. TLR
stimulation can also activate nuclear factor (NF)-κB,
such that p65/p50 heterodimers are formed and lead to the
production of hypoxia-inducible factor (HIF)-1α [15,21,22].
This protein, found in the presence of low oxygen concen-
trations, regulates the NOS2 gene to increase the secretion
of inducible nitric oxide synthase (iNOS) [21], toxic nitric
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oxide (NO), and reactive oxygen intermediates (ROI) [19]. A
chemokine profile for classically activated macrophages may
include HCC-2 (CCL15), macrophage inflammatory protein
(MIP)-3α (CCL20), and B cell attracting chemokine-1
(CXCL13), as well as IFN-γ-inducible chemokines such as,
monocyte chemotactic protein (MCP)-1 (CCL2), interferon-
inducible T cell alpha chemoattractant (I-TAC) (CXCL11),
interferon gamma-induced protein 10 (IP-10) (CXCL10)
and monokine induced by gamma interferon (MIG)
(CXCL9) [7,18,20-22]. Production of these chemokines
can be a result of previously mentioned transcription fac-
tors STAT1 or NF- κB [16,18]. These chemokines also
coordinate natural killer (NK) and Th1 cell responses,
integrating classically activated macrophages into the amp-
lification and regulation of polarized T cell responses
[20,21]. Surface molecules expressed by classically acti-
vated macrophages include elevated amounts of MHC
class II receptors; costimulatory molecules CD80 and
CD86; IL-2Ra, IL-15Ra and IL-7R; and low levels of man-
nose receptor C type 1 (MRC1) and Fcγ RII [17,18,20].
Each of these characteristics allow classically activated
macrophages to be potent effector cells that mediate re-
sistance against bacterial, viral, and fungal infections as
well as tumor cells [18,19]. They are also important in the
inflammatory stages of wound healing and the foreign
body response (FBR) to biomaterials [23-25].
Alternatively activated, previously known as M2 mac-
rophages, are said to be pro-angiogenic, promoting tis-
sue remodeling and repair. This phenotype arises when
IL-4 activates the IRF/STAT signaling pathway via STAT6
[7,10,15-18]. IL-10, on the other hand, activates STAT3-
mediated alternative activation and gene expression
[7,15-18]. This STAT-mediated activation of macrophages
is regulated by the suppressor of cytokine signaling (SOCS)
family: where IL-4 can upregulate SOCS1, inhibiting the
action of STAT1, but IFN-γ and TLR stimulation cause
SOCS3 to be upregulated to prevent the activity of STAT3
[16,26]. The transcription factors STAT3 and STAT6 allow
for high-level production of the cytokines IL-10, IL-1 re-
ceptor antagonist (IL-1Rα), IL-4Rα, TGF-β, and the type II
IL-1 decoy receptor [16,18,20,21]. Other genes activated by
STAT6 include mannose receptor (Mrc1), resistin-like
α (Retnla/Fizz1), and chitinase 3-like 3 (Chi3l3/Ym1).
For STAT3, some of the genes expressed are Il10, Tgfb1,
and Mrc1 [16]. STAT6 also coordinates with peroxisome
proliferator-activated receptors PPARγ and PPARδ, as well
as Krüppel-like factor (KLF)-4, to induce some alternative
genes (Arg-1, Mrc1, Fizz1, PPARγ) while inhibiting genes
associated with classical activation (TNFa, Cox-2, CCL5,
iNOS) by preventing NF-κB activation [16]. However, NF-
κB activation and the formation of p50 homodimers are
also important in alternative activation and resolution of
inflammation [15,21,22]. Chemokines induced by IL-4 or
IL-13 alternative activation include monocyte chemotactic
protein (MCP)-4 (CCL13), MCP-2 (CCL8), MCP-1 (CCL2),
macrophage-derived chemokine (MDC) (CCL22), alternative
macrophage activation-associated chemokine (AMAC)-1
(CCL18) and eotaxin-3 (CCL26) [7,18,20-22]. CCL22
specifically attracts Th2 and Treg cells, showing that
alternative macrophages are also involved in the polarization
of T cell responses [21]. Macrophages activated by IL-
10, TGF-β, and GC produce the chemokines eotaxin-2
(CCL24), IP-10 (CXCL10), I-TAC (CXCL11), and regulated
on activation, normal T cell expressed and secreted
(RANTES) (CCL5) [20,21]. Other factors produced include
vascular endothelial growth factor (VEGF), matrix metallo-
proteinases (MMPs); and HIF-2α to regulate ARG1 and the
arginase pathway to produce ornithine and polyamines
[18]. The exception to alternative activation is the pheno-
type of macrophages induced by Ic; they retain the ability
to produce high levels of pro-inflammatory cytokines [18].
Overall, alternatively activated macrophages are efficient
phagocytic cells with the expression of mannose and galact-
ose receptors; CD163, TLR8, TLR1, and IL21a; and MRC1
and scavenger receptor type 1 (SR-A1) [17,18,20]. They are
involved in parasite containment, tumor progression, and
function to dampen immune responses [12]. In the reso-
lution stages of the FBR, alternative macrophages drive the
wound healing response, often leading to fibrotic encapsu-
lation and failure of implanted devices and scaffolds [23,25].
Review
Macrophages as cancer therapeutic targets
Tumor-associated macrophages
Tumor-associated macrophages (TAMs) have properties
consistent with alternatively activated macrophages [27].
They produce cytokines like IL-10 and TGF-β [21]. The
polarization of macrophages recruited to a tumor site,
or any other tissue, is highly dependent on the cytokines
present. The production of both IL-10 and TGF-β sup-
presses anti-tumor activities of the immune system allow-
ing tumor cells to avoid destruction by immune cells [28].
TAMs have been found to be poor producers of NO and
ROIs, which are typically products of classically activated
macrophages [29]. In addition, TAMs express low levels of
cytokines such as IL-12, TNF-α, and IL-6 [29]. Lastly,
TAMs have been found to be poor antigen-presenting
cells indicating that they do not have the potent effector
cell functions attributed to classically activated macro-
phages [19]. This information establishes that TAMs rep-
resent a subset of alternatively activated macrophages, and
that many of their byproducts enhance tumor growth and
angiogenesis.
While angiogenesis plays a central role in the progres-
sion of tumors from benign to malignant, there are many
other factors involved. MMPs contribute to tumor inva-
sion through matrix remodeling where they are capable of
cleaving extracellular matrix (ECM) proteins [29], which
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normally provide a barrier for tumor growth. These MMPs
along with other proteases such as plasmin and urokinase-
type plasminogen activator (uPA) are all produced by
TAMs [21,29]. The continued proliferation and growth
aided by TAMs can lead to metastasis of tumor cells. In
metastasis, it is suggested that primary tumors are able
to release factors that increase a metastatic outcome at
other sites. These sites are referred to as premetastatic
niches where the factors secreted by primary tumors
cause the accumulation of myeloid progenitor cells [30]. A
recent study has shown that TAMs play an important role
in controlling the survival, migration and growth of meta-
static cells to these niches [31]. TAMs were also found to
enhance tumor cell extravasation, establishment and sub-
sequent growth in surrounding tissue. The involvement of
TAMs in tumor angiogenesis, growth, progression and
metastasis makes them attractive targets for anti-cancer
therapeutics. Therapeutic strategies directed at TAMs
fall into four categories: reduction of effector function,
limiting recruitment, prevention of pro-tumor polarization,
and macrophage reprogramming [32,33]; the benefits
and drawbacks of which are outlined in Table 1 [33-42].
Anti-angiogenic therapy
Angiogenesis must occur in tumors for them to grow
even small amounts [35]. This process can be influenced
via a multitude of factors that are induced in hypoxic
regions including VEGF, placental growth factor (PlGF),
angiopoietins (ANGs), colony stimulating factor (CSF)-
1, and CCL2/MCP-1 [35]. Anti-angiogenic therapy via
the VEGF pathway, the primary angiogenic pathway of
macrophages, is ineffective, as tumor cells are able to acti-
vate other pro-angiogenic pathways [36]. However, macro-
phage angiogenic abilities can be indirectly prohibited
through the use of other factors. When a tumor develops
regions of inadequate oxygen supply, HIF1-α subunits are
stabilized, recruiting bone marrow (BM)-derived cells in-
cluding macrophages that up regulate angiogenesis. The
elimination of HIF1-α from the tumor environment pro-
vides a potential anti-angiogenic cancer therapy pathway
by inhibiting the recruitment of macrophages and other
pro-angiogenic cells [43]. HIF1-α knockout mice (HIFko)
with glioblastoma (GBM) tumors, show a decrease in
angiogenesis when compared to HIF functional mice with
tumors [43].
ANG2 is produced by endothelial cells in hypoxic envi-
ronments and would typically recruit pro-angiogenic cells,
however binding of ANG2 with a monoclonal antibody
inhibited angiogenesis by blocking the interaction of
ANG2 with TIE2-expressing monocytes [44,45]. TIE2-
expressing monocytes are a subpopulation of TAMs that
have the greatest role in tumor angiogenesis [44]; prevent-
ing activation of these cells can halt their angiogenic activ-
ity and disable further recruitment of pro-angiogenic cells.
Blocking of ANG2 with a monoclonal antibody inhibits
tumor growth; causes regression of tumor vasculature by
inducing apoptosis in some pro-angiogenic cells; and
hinders progression of some late stage cancers (Figure 1)
[45]. While the anti-angiogenic treatments mentioned here
have not been shown to be extremely efficient alone, they
may be used in combination with other chemotherapeutics
to improve the outlook for patients [34,37,42].
Recruitment inhibition
Another option for targeting TAMs is to inhibit the recruit-
ment of monocytes to the primary tumor site [38,39].
CXCL12 is a chemokine that is thought to regulate the
migration of BM-derived cells, facilitating their transmi-
gration through endothelial cell barriers into the tumor
microenvironment [46]. Also, secretion of CXCL12 by
stromal cells outside of the tumor microenvironment at-
tracts cancer cells via their upregulated CXCR4 receptor
[46]. Thus, several CXCR4 antagonists are being studied
as additive cancer therapeutics to reduce tumor infiltra-
tion by BM-derived cells and prevent further metastatic
spread [38]. One antagonist of interest is CTCE-9908,
which is a chemokine-based therapy [47-49]. In prostate
cancer cell lines (PC-3-Neo and PC-3-Bcl-2 transfected
with Bcl-2), treatment with CTCE-9908 reduces VEG-
FR1and CD11b expressing cells [49]. Both VEGFR1 and
CD11b are expressed on tumor-infiltrating cells that pro-
mote angiogenesis [15,35,36,50]. Phase II clinical trials in
hepatocellular carcinoma using CTCE-9908 have also
been initiated [51].
CCL2 is a chemokine that has been heavily investigated
in prostate, ovarian and breast cancers because CCL2 reg-
ulates the recruitment of monocytes and macrophages to
tumors and other sites of inflammation [38,52]. In recent
glioma therapy studies, a mAB-based CCL2 blockade re-
duced the percentage of CD11b+CD45+ TAMs by about
Table 1 Advantages and disadvantages of anti-cancer therapies targeting macrophage behaviors
Approach Advantages Disadvantages
Anti-angiogenic therapy Inhibit tumor growth and prevent metastasis [33,34],
improves efficacy of chemotherapeutics [35]
Must be used in combination with chemotherapeutics [36];
systemic effects [36,37]
Recruitment inhibition Prevent macrophages from entering tumor,
becoming TAMs [38,39]
Systemic effects [38]
Macrophage reprogramming Macrophages secrete tumoricidal molecules [40,41] Local delivery necessary to avoid altering systemic Th1/Th2
paradigm [42]
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50% and decreased the total number of these cells five-
fold (Figure 2) [53]. In a previous study, the use of anti-
CCL2 decreased the overall burden of prostate tumors
in vivo by 96% after 5 weeks [54]. Combining this therapy
with the already in use, anti-mitotic chemotherapy medi-
cation, Docetaxel, further improved the results [54].
Since then, more work has been done to examine the
synergy of these two treatments in preventing metastasis
of primary prostate cancer to bone [55,56].
As CD11b is a macrophage receptor that is import-
ant in recruitment to tumor sites, a CD11b antibody
provides another treatment option for TAM targeted
cancer therapy [50]. The use of a monoclonal CD11b
antibody both enhances tumor response to radiation
and reduces infiltration of myeloid cells [50]. Based on
these examples, the targeting of chemokines and
chemokine receptors has resulted in an effective en-
hancement of anti-cancer therapies by showing both
Figure 1 Masson’s trichrome staining of orthotopic, late-stage MMTV-PyMT mammary tumors treated according to an extended (9 weeks)
treatment schedule. Collagen’s blue staining demonstrates abundant fibrotic tissue and scant tumor cells in 3.19.3-treated tumors (day 78). Left
panels show tumor periphery. Scale bars, 600 mm (left panels) and 300 mm (right panels). Images are representative of five 3.19.3-treated (day 78)
and three control IgG-treated (day 48) tumors. Reproduced with permission [45].
Figure 2 C57BL/6 mice bearing GL261 glioma received 2 mg/kg/dose (approximately 40 μg/mouse) anti-mouse CCL2 mAb or control
IgG twice weekly by i.p. injections starting on day 7 after tumor cell inoculation (n = 5/group). On day 24, mice were euthanized and
isolated BILs were pooled from all mice in the same treatment group, and evaluated by flow cytometry for surface expression of CD11b and
CD45 (A). Absolute numbers of CD11b + CD45 + (p = 0.0008) (B). Reproduced with permission [53].
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decreased tumor size and prevention of tumor metas-
tasis [38,39].
Macrophage reprogramming
Macrophage plasticity has led to the idea of utilizing
macrophage reprogramming to synergistically act with
chemotherapeutics. Many of the ways in which TAMs
contribute to tumor development and survival are specific
to the alternatively activated phenotype. Thus, being able
to prevent TAMs from alternatively differentiating or pro-
moting reprogramming of TAMs to classical macrophages
will prevent tumor growth.
Several mechanisms of M2 macrophage polarization
have been studied, and these pathways may also prove
to be viable targets in cancer therapeutics. Jumonji do-
main containing-3 (Jmjd3) is a histone 3 Lys27 (H3k27)
demethylase that has been implicated in regulating M2
macrophage polarization [57]. A deficiency of Jmjd3 re-
sults in trimethylation of H3k27 on the gene Irf4, which
encodes a key transcription factor M2 activation [57]. Re-
active oxygen species (ROS) production has also been
found to play a critical role in macrophage differentiation
[58]. Specifically, inhibition of superoxide (O2−) production
prevents M2 macrophage polarization but does not hinder
the M1 phenotype [58]. Thus, blocking of the Jmjd3-Irf4
axis or ROS production may be potentially effective
methods for added tumor inhibition.
The differentiation of infiltrating monocytes into TAMs
also results from cytokines like IL-4, IL-10, and IL-13. The
use of IL-3 has been successful at inhibiting IL-4 produced
by basophils, resulting in macrophages skewed towards a
classical polarization [59]. SHIP (src-homology 2-containing
inositol 5' phosphatase) is a molecule that negatively regu-
lates the phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K) apoptotic pathway. In cancers, the PI3K pathway
is overactive, allowing malignant cells to avoid apoptosis,
essentially becoming immortal. It has been determined that
basophils produce SHIP in response to IL-3, which can
then inhibit IL-4 production necessary for TAM activation
(Figure 3) [59].
Many tumor-infiltrating monocytes are alternatively acti-
vated by cytokines released by existing tumor cells [41].
However, the added presence of classical activators such
as CpG oligodeoxynucleotides (CpG) and an anti-CD40
agonist can increase anti-tumor activity of macrophages.
CpG causes a pro-inflammatory response in macrophages
and the agonistic anti-CD40 can reverse immune suppres-
sion. As a follow up study to those that indicated that the
synergistic effects of anti-CD40 and CpG increase classical
activation [40], a combination of anti-CD40, CpG, and
the chemotherapeutic agent cyclophosphamide was
used to study treatment of melanoma in vivo. In this
combinatorial study, there was an approximate ten-fold de-
crease in tumor size and survival was extended by ~12 days
[60]. There was also an increase in the percentage of F4/80
+Gr1+ inflammatory monocytes [60,61].
Reprogramming of existing TAMs to be classical mac-
rophages is another valid approach to improve upon con-
ventional anticancer therapies. IFN-α has long been known
to be tumoricidal and was the first cytokine to show some
benefit in the treatment of some cancer types [62]. Because
of the protein’s short half-life, however, the dose required
Figure 3 Repressing IL-3-induced M2 macrophages through inhibiting IL-4 production from basophils. (A) IL-3 and GM-CSF stimulate the
production of more IL-4 from SHIP−/− than SHIP+/+ Lin- BM cells. SHIP+/+ and SHIP−/− Lin- BM cells were cultured with M-CSF, IL-3, or GM-CSF for
24 h and supernatants were subjected to IL-4 ELISAs. Data shown are the means ± SEM of duplicate determinations. *, p < 0.05 compared with
unstimulated cells. (B) Model of IL-3-induced M2 skewing and the role that SHIP plays in this process. IL-3 stimulates the proliferation and
differentiation of both basophil precursors and monocyte/macrophage progenitors. IL-3 also stimulates the production of IL-4 from basophils
and basophil progenitors in a STAT5-dependent manner. SHIP within the basophils represses this IL-4 production. The secreted IL-4, in turn,
skews, via STAT6, the maturing and mature MΦs to an M2 phenotype. Copyright 2009. The American Association of Immunologists, Inc. [59].
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for efficacy becomes toxic to healthy tissue and the tumor
is only exposed to short bursts of therapy [62]. This is why
the use of TIE2-expressing monocytes, which are regularly
recruited to tumor sites, to selectively deliver IFN-α, can
inhibit angiogenesis and skew macrophage polarization
to the classical end of the spectrum [62]. This is shown
by the presence of cells expressing Iba1, a monocyte/
macrophage/microglia protein, in and around the tumor
site.
Histidine-rich glycoprotein (HRG), a host produced anti-
angiogenic and immunomodulatory factor to promote
TAM reprogramming is another viable target [63]. HRG
has been studied to identify mechanisms by which it medi-
ates anti-tumor effects; and the results revealed that
TAMs activated by HRG down regulated expression of
pro-angiogenic cytokines and upregulated that of angio-
static cytokines. At the same time, HRG activated TAMs
showed improved quality of existing vasculature causing
an increase in the effectiveness of other chemotherapeutics
[63]. Another target for reprogramming TAMS is the NF-
κB signaling pathway [64]. Inhibition of NF-κB signaling
was found with IκB kinase (IKK)β reduction, stimulating
TAMs to become cytotoxic through recruitment of NK
cells with the production of IL-12 [64]. These three exam-
ples, along with many more, provide proof-of-concept
data for the reprogramming of macrophages in cancer
therapeutics.
Macrophages and scaffolds for tissue engineering
Macrophages are involved in ECM remodeling, prolifer-
ation of epithelial cells, development of vasculature and
the organization of tissues during development [65]. These
functional capacities of macrophages extend into the
wound healing response and the FBR to biomaterials.
Macrophage phenotype is dynamic throughout the course
of these processes, and the balance between phenotypes is
instrumental in the timely progression of these responses
from injury to successful healing. As with TAMs, macro-
phages involved in healing retain their plasticity and alter
their phenotype in response to a variable cytokine micro-
environment in the progression of these processes [6].
Overview of the foreign body response to implanted
scaffolds
Surgical implantation or injection of a biomaterial-based
construct injures the tissue, resulting in an influx of blood
and cell death. Dying cells release danger signals (danger
associated molecular patterns, DAMPs) that induce local
inflammation [66] and activate resident macrophages
[67,68]. These DAMPs include HMGB1, histones, and
uric acid [66,67,69,70]. Blood proteins such as albumin,
fibrinogen, fibronectin, immunoglobulin G (IgG), and vari-
ous complement proteins adsorb to the surface of the bio-
material [71]. Activation of the complement cascade results
in opsonization of the biomaterial surface with C3b and
induces inflammation through the anaphylatoxins C3a
and C5a [72]. These anaphylatoxins recruit leukocytes
to the site of inflammation, cause histamine release from
mast cells, and induce oxidative bursts in neutrophils [73].
Release of histamine from mast cells attracts neutrophils
and monocytes [74,75]. Neutrophils are the first immune
cells to arrive at the implant site [76] and, along with
mast cells, secrete IL-4 and IL-13 early in innate immune
responses [9].
Monocytes are the next immune cells to extravasate
into the tissue where they differentiate into tissue macro-
phages [77]. These macrophages are classically activated
upon the adsorbed protein layer [78,79]. Proteins, such as
fibrinogen, C3, and C3b on the surface of the biomaterial
are bound by the integrin αMβ2 (CD11b:CD18), also
known as complement receptor 3 (CR3), on the surface
of macrophages [77,80-82]. Activated macrophages se-
crete TNF-α, IL-6, IL-8, MCP-1, RANTES, ROS, iNOS,
IL-1β, and MMPs [83-85]. The chemokines MIP-1α,
IL-8, and MCP-1 attract additional monocytes [83]. These
biomaterial-activated macrophages are also characterized
by an increased phagocytic capacity [86]. Continued pres-
ence of pro-inflammatory macrophages causes acute in-
flammation to morph into chronic inflammation [87].
Attempted phagocytosis of biomaterials leads to the
fusion of adherent classically activated macrophages into
foreign body giant cells (FBGCs) [88]. IL-4 and IL-13 in-
duce the fusion of adherent macrophages [88]. β1 and β2
integrins are involved in the fusion of these macrophages
[89], and CCL2 guides the chemotaxis of adherent macro-
phages towards each other [90]. FBGCs have a cytokine
profile more characteristic of alternatively activated mac-
rophages that includes TGF-β, platelet derived growth fac-
tor (PDGF), IL-1rα, and IL-10 [9,77,84,91]. FBGCs secrete
protons, ROS, and MMPs in an attempt to eradicate the
foreign body [92,93]. Like M1 macrophages, FBGCs se-
crete pro-inflammatory RANTES and the chemoattractant
MCP-1 [84]. ECM breakdown by MMPs leads to increased
DAMPs in the microenvironment and further macrophage
activation [94].
The resolution stage of the FBR is dominated by alter-
natively activated macrophages. A profibrotic, alternatively
activated, wound healing macrophage phenotype results
from macrophage phagocytosis of dying cells, stimulation
by IL-4 or by IL-13 [12,95]. These dying cells include
epithelial and endothelial cells that are damaged by pro-
inflammatory cytokines, such as TNF-α, and short-lived
neutrophils [25,96]. Alternatively activated macrophages
secrete profibrotic mediators such as TGF-β, IL-4, IL-13,
IL-10, arginase, and ECM components [9,97]. These
macrophages drive the wound healing response by acti-
vating mesenchymal cells that participate in the wound
healing process [98,99]. TGF-β can also induce an M2-
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like phenotype in macrophages [100]. These M2 macro-
phages are profibrotic, but are still unable to reduce the
pro-inflammatory response. Reduction of chronic in-
flammation requires IL-10-induced activation of regula-
tory M2-like macrophages [9,101]. These macrophages
secrete high levels of the same protein that activates them
[9]. IL-10 prevents the translation of pro-inflammatory
cytokines by macrophages through STAT3 [102,103].
As in the immune response to parasitic infections, the
early phase of wound healing and the FBR is characterized
by M1-like macrophages and the late phases are controlled
by M2-like macrophages [25,91,104-106]. In the healing of
aseptic wounds regulatory M2 (IL-10 stimulated) macro-
phages rapidly downregulate the inflammatory response to
promote tissue repair [9,107-110]. Conversely, in the FBR,
further activation of macrophages will occur, resulting
in continued chronic inflammation (pro-inflammatory
macrophages and FBGCs) and continued wound healing
(wound healing macrophages).
It has long been hypothesized that chronic inflammation
is present until an extensive fibrous capsule surrounds the
biomaterial [76]. Resident fibroblasts, fibrocytes, and mac-
rophages are activated by TGF-β, and become myofibro-
blasts [111-115]. Myofibroblasts secrete high amounts of
collagen I, collagen III, and fibronectin [110,116]. The ex-
pression of α-smooth muscle actin (α-SMA) permits myo-
fibroblasts to contract collagen networks in a process
known as contractile scarring [117,118]. Incessant acti-
vation of myofibroblasts results in continued secretion
and contraction of ECM components. This eventually
results in excessive scarring, and fibrous encapsulation.
The fibrous capsule is a dense, hypocellular, avascular
collagenous network that reduces the diffusion of all
molecules, and results in the failure of scaffolds for
applications in tissue engineering [119,120]. The entire
process leading up to fibrous encapsulation is illustrated
in Figure 4.
Scaffolds to instruct phenotypic macrophage responses
Depending on biomaterial properties and the cytokines
secreted by inflammatory cells in the biomaterial micro-
environment, macrophages adopt either an M1- or M2-
like state [23]. As macrophages are plastic, they can exist
on a spectrum between these two states. This leads to
the hypothesis that surface chemistry and physical prop-
erties of scaffolds can be used to polarize macrophages
towards a specific phenotype, or away from another. In
particular, some scaffolds have been engineered to reduce
prolonged activation of M1-like macrophages, so that cell-
laden scaffolds maintain cell viability [121,122]. Additional
scaffolds have been engineered to reduce excessive fibrosis
and decrease time to incorporation of the implant [123]. A
balance in macrophage phenotype must be achieved for
scaffold vascularization.
Varied scaffold chemistries suggest the ability to decrease
the expression of M1 macrophages. Microgel conform-
ational coatings formed from poly(N-isopropylacrylamide)
(pNIPAm) and poly(ethylene glycol) diacrylate (PEGDA)
reduce fibrinogen adsorption, macrophage adhesion,
macrophage spreading, and secretion of inflammatory
cytokines [124]. Zwitterionic hydrogels are able to re-
duce protein adsorption and are characterized by anti-
inflammatory, pro-healing macrophages that promote
angiogenesis and show no evidence of a collagenous
capsule for longer than three months [125]. The ability
of macrophages to induce positive tissue remodeling
on fourteen different biologically-derived surgical meshes
was investigated, and suggested that a predominance of
M2 macrophages could potentially lead to more construct-
ive tissue remodeling after two weeks [23]. Sugisis and
Matristem scaffolds – derived from porcine small intestinal
submucosa, and urinary bladder, respectively – appeared
to increase macrophage infiltration; whereas the other scaf-
folds, derived from human and porcine dermis, appeared
to prolong the healing response and exhibited an increase
in M1-like macrophages [23].
In addition to chemical properties, physical proper-
ties of scaffolds can significantly influence macrophage
phenotype. Controlling the pore size of scaffolds is
one technique that shows promise in decreasing pro-
inflammatory macrophage presence and improving the
healing outcome. A pore size of 30–40 μm within porous
template scaffolds formed of five different synthetic poly-
mers and one natural polymer appeared to increase infil-
tration of macrophages and vascular density, suggesting
that these materials induce regenerative macrophages
[126-128]. It is generally thought that geometric restric-
tion of macrophages within these pores prevents them
from spreading out into their phagocytic, inflammatory
phenotype [24,129,130]. Vascular density is suggested to
peak at pores size of 35 μm [126,131]. The degree of
porosity in a material can also influence macrophage
phenotypes, with more porous materials leading to de-
creased healing time of implants and, therefore, a reduced
fibrous capsule thickness. For example, even though por-
ous polytetrafluoroethylene (PTFE) surfaces seemed to in-
duce inflammatory cytokine secretion by macrophages,
a thinner fibrous capsule was formed on porous versus
nonporous PTFE [132]. BMDMs cultured on electrospun
polydioxanone (PDO) of larger fiber length and pore size
showed increased arginase, TGF-β, VEGF, and basic fibro-
blast growth factor expression, characteristic of alterna-
tively activated macrophages, than those cells cultured on
scaffolds with smaller fiber length and pore size [123].
Substrate morphology and surface topography repre-
sent two other physical properties of scaffolds that are
thought to influence macrophage phenotype and thus
the foreign body response and material biocompatibility.
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Figure 4 Macrophage phenotype in the wound healing and foreign body responses.
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2D and 3D sP(EO-stat-PO) surface modified poly(D,L-
lactide-co-glycolide) (PLGA) substrates were compared
to find that the flat surfaces studied in this work lead to
pro-inflammatory cytokine profiles while 3D nanofibers
resulted in increased pro-angiogenic chemokines and
angiogenesis [133,134]. Micro- and nano-structured sur-
faces have also been examined to determine the effect of
surface topography on macrophage behavior [135-140].
Several studies have suggested macrophage responses
are more greatly impacted by micro-patterned surfaces
than corresponding nanostructures [135-137,140], how-
ever, few distinctive correlations have been revealed. Some
trends indicate that larger posts or widely separated posts
on material surfaces induce anti-inflammatory phenotypes
in macrophages [135,136], while others suggest that nano-
structured versus microstructured grooves decrease the
pro-inflammatory response of macrophages [137,138,140].
Another surface property that has been examined with
respect to macrophage phenotype is fiber diameter and
orientation. Results from these studies indicate that aligned
rather than randomly oriented nanofibers minimize in-
flammatory responses [121,141].
The processing of biologic scaffolds appears to alter
macrophage phenotype. Processing of scaffolds such as
subintestinal submucosa with a carbodiimide crosslinker
can lead to a predominately M1 response resulting in
chronic inflammation and prolonged healing; whereas
the non-crosslinked scaffold appeared to induce a large
M2-like response and constructive remodeling at sixteen
weeks [24]. A low degree of acetylated chitosan scaffolds
(5%) is suggested to induce a macrophage response char-
acteristic of M2 macrophages and a reduced fibrous
capsule. However, the 15% degree of acetylation resulted
in adherent, activated pro-inflammatory macrophages
[122,142], which again suggests that surface chemistry
plays a role in macrophage response. Infiltration of blood
vessels into a glutaraldehyde-crosslinked collagen scaffold
was characterized by coordinated levels of M1- and M2-
like macrophages [143].
It is suggested herein that a temporal balance between
pro-inflammatory, wound healing, and regulatory (IL-10
stimulated) macrophages may be necessary for successful
implantation of a scaffold for tissue engineering applica-
tions. Scaffold chemistry, pore size, and processing condi-
tions appear to have the potential to regulate macrophage
phenotype, and, therefore, the extent of inflammation, fi-
brous encapsulation, and angiogenesis of these materials.
The effects of these biomaterial properties on macrophage
phenotype are outlined in Table 2.
Conclusions
Based on the information discussed here, it can be con-
cluded that macrophages are an appealing and effective
target for supplementing current cancer treatments. Thus
far there is a lack of research leading to an understanding
of how to achieve the appropriate balance of macrophage
phenotypes at tumor and implant sites. In targeting
macrophages with cancer therapeutics, the intention is to
develop localized and target-specific treatment options.
Several challenges exist and are outlined in Table 1
[36-38,42]. One such challenge lies in complete repro-
gramming to classically activated macrophages, which
could yield a systemic loss of alternative macrophages
resulting in hazardous levels of cytotoxic cytokines and
significant amounts of tissue damage [9]. Classical mac-
rophages are also necessary for basic immunological
responses to infection, so an exclusively alternative macro-
phage population may leave patients susceptible to routine
infections. Lastly, alternative macrophages are extremely
important in wound healing and a deficiency may leave
tissues unrepaired with no chance for recovery. Exploiting
macrophages to co-opt tumors holds a number of advan-
tages that could synergistically interact with existing che-
motherapeutics. However, several challenges remain in
reprogramming macrophages in the tumor microenviron-
ment, including targeted delivery to the tumor site and
Table 2 Biomaterial influence on macrophage phenotype
Biomaterial property Macrophage response
Large fibers and pores (PDO) M2 response, wound healing,
angiogenesis [123]
Fiber size
~0.6 μm (PLLA) Minimal M1 activation, low FBGC
population [121]
~1.6 μm (PLLA) High FBGC population [121]







Reduction of M1 activation and
cytokine secretion [124]




Crosslinked with carbodiimide M1 bias, chronic inflammation,
prolonged healing [24]
Non-crosslinked M2 bias, constructive
remodeling [24]
Acetylated chitosan
5% acetylated Predominately M2, reduced
fibrous capsule [122,142]









M2, timely constructive tissue
remodeling [23]
Human, porcine dermis M1, prolonged healing [23]
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selective delivery to alternatively activated TAM popula-
tions. Immunomodulation of macrophages may also result
in improved success of implants for tissue engineering. In
the FBR, the complete absence of M1 macrophages is
detrimental in the progression of the response. Specific-
ally for successful implantation of a scaffold for tissue
engineering, M1 macrophages are necessary to instigate
the inflammatory response and initiate the M2-
coordinated wound healing process. Timely resolution of
the response requires the presence of IL-10high M2 macro-
phages. Though many of the materials mentioned here
lead to a timely resolution of the FBR and successful
vascularization, these materials cannot be used for all tis-
sue engineering applications. Therefore, strategies to
modulate macrophages in the tumor and biomaterial
microenvironment require consideration of the desired
end result.
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